Molnupiravir is effective in patients with haematological malignancies

Bołkuń, Łukasz; Puła, Bartosz; Kołkowska‐Leśniak, Agnieszka; Morawska, Marta; Cichocka, Edyta; Charliński, Grzegorz; Garus, Bartosz; Giebel, Sebastian; Piszcz, Jarosław; Drozd‐Sokołowska, Joanna; Kwiatkowski, J; Biernat, Monika; Hus, Iwona; Lech‐Marańda, Ewa; Długosz‐Danecka, Monika; Giannopoulos, Krzysztof; Wróbel, Tomasz

doi:10.1002/ijc.34442

Cited by 6 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a cohort of 175 hematological patients treated with Molnupiravir, of whom 77% were vaccinated, the rates of hospitalization and death at 28 days were 20% and 4% respectively. These outcomes were better than those previously reported in vaccinated hematological patients [120]. A matched-paired analysis from the EPICOVIDEHA registry, comparing the use of Molnupiravir versus Nirmatrelvir/ritonavir in 232 patients with HM (including only 9 with CLL), reported similar rates of SARS-CoV-2 severity, hospitalization or mortality between the two drugs [121].…”

Section: Other Strategies To Mitigate Risk Of Severe Infectionmentioning

confidence: 78%

COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?

Harel,

Itchaki

2023

Acta Haematol

View full text Add to dashboard Cite

Background: Chronic lymphocytic leukemia (CLL) is a prevalent hematological malignancy (HM) characterized by inherent immunodeficiency, which is further pronounced by disease-directed therapy. The COVID-19 pandemic has had devastating outcomes, and although its impact has diminished over time, it continues to be a cause of significant morbidity and mortality, particularly among immunodeficient patients. Summary: In this review, we describe mechanisms of immune dysfunction in CLL in relation to COVID-19, provide an overview of the clinical outcomes of the disease in this patient population, and identify risk factors associated with severe morbidity and mortality. Additionally, we acknowledge the influence of the rapidly evolving landscape of new disease variants. The review further delineates the humoral and cellular responses to vaccination and their clinical efficacy in preventing COVID-19 in CLL patients. Moreover, we explore potential approaches to enhance these immune responses. Pre- and post-exposure prophylaxis strategies are discussed, along with description of common agents in the treatment of the disease in both outpatient and inpatient setting. Throughout the review, we emphasize the interplay between novel therapies for CLL and COVID-19 outcomes, prevention, and treatment and describe the impact of COVID-19 on the utilization of these novel agents. This information has the potential to guide clinical decision making in the management CLL patients.

show abstract

Section: Other Strategies To Mitigate Risk Of Severe Infectionmentioning

confidence: 78%

COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?

Harel,

Itchaki

2023

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Additionally, early therapeutic strategies, particularly the use of targeted antivirals and monoclonal antibodies, were crucial in enhancing patient outcomes. 35 , 36 , 37 These early treatments not only reduced the severity of the illness but also led to decreased mortality rates. 10 , 11 , 18 …”

Section: Discussionmentioning

confidence: 99%

Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Salmanton-García,

Marchesi,

Farina

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

“…There was no increase in the incidence of adverse events in the molnupiravir 800 mg/day group compared to 200 mg/day and 600 mg/day groups [ 90 ]. The efficacy of molnupiravir and its favorable safety profile were also confirmed in patients with HM [ 58 ]. Other publications indicated that the use of molnupiravir in patients with severe or moderate COVID-19 did not bring clinical effects [ 91 ].…”

Section: Molnupiravir (Lagevrio)mentioning

confidence: 99%

COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic

Hus

Szymczyk

Mańko

et al. 2023

Biology

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic is undoubtedly the most difficult health challenge of the 21st century with more than 600 million laboratory-confirmed SARS-CoV-2 infections and over 6.5 million deaths worldwide. The coronavirus pandemic contributed to rapid development of mRNA vaccines, which, along with new antiviral drugs, have been the subject of extensive research for many decades. Nevertheless, elderly, multi-morbid and immunocompromised patients continue to face a more severe clinical course and a higher risk of death from COVID-19, even now that the risk of COVID-19 in the general population is significantly reduced due to the introduction of global vaccination strategies. In this paper, we present the mechanisms of increased susceptibility to infectious complications and the evolution of the clinical course of COVID-19 in patients with hematological malignancies, taking into account the mutation of the virus and the introduction of vaccines and new antiviral drugs. We also present current recommendations for prophylactic and therapeutic management in patients with hematological malignancies.

show abstract

Molnupiravir is effective in patients with haematological malignancies

Cited by 6 publications

References 22 publications

COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?

COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?

Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic

Contact Info

Product

Resources

About